SS-31 (Elamipretide) · Research brief

Best SS-31 for Cellular Energy — Research-Grade Guide

Real Peptides Research TeamEditorial

Updated April 1, 202612 min read

58 WORDS

Short answer

Key takeaways

SS-31 (elamipretide) stabilizes cardiolipin on the inner mitochondrial membrane, preventing oxidative damage to respiratory chain supercomplexes and restoring ATP synthesis efficiency in compromised mitochondria.
Research-grade SS-31 requires HPLC purity ≥98% with mass spectrometry confirmation at 640.77 Da. Lower purity preparations contain Dmt-substituted or truncated peptides that compete for binding without therapeutic effect.
The peptide's half-life in circulation is 3–4 hours, but mitochondrial residence time extends to 12–16 hours due to electrostatic anchoring to cardiolipin, creating dosing schedules based on tissue accumulation rather than plasma kinetics.
Lyophilized SS-31 must be stored at ≤-20°C; reconstituted solutions remain stable at 2–8°C for 28 days, but freeze-thaw cycles reduce bioactivity by 15–20% per cycle.
Therapeutic effects are most pronounced in tissues with high mitochondrial density and metabolic demand. Heart, brain, skeletal muscle, kidney. Where baseline mitochondrial coupling efficiency is impaired.
Subcutaneous dosing of 3–5 mg/kg in rodent models and 0.1–10 μM in cell culture represent the validated therapeutic range; doses above 50 μM produce off-target membrane toxicity.
Endotoxin contamination above 0.5 EU/mg confounds inflammation and oxidative stress measurements. LAL assay documentation is non-negotiable for interpretable data.

Most cellular energy research focuses on substrates. Glucose, ketones, fatty acids. But those pathways assume the mitochondria processing them are structurally intact. They often aren't. SS-31 (elamipretide), a tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2, represents one of the only compounds that directly targets mitochondrial membrane architecture rather than metabolic signaling upstream. It doesn't increase substrate availability or activate AMPK. It physically stabilizes cardiolipin, the phospholipid that anchors the electron transport chain complexes together on the inner mitochondrial membrane. When cardiolipin oxidizes, ATP synthase efficiency collapses. SS-31 prevents that.

We've worked with research institutions using SS-31 in models ranging from ischemia-reperfusion injury to age-related mitochondrial decline. The consistency across models is striking. The peptide localizes to mitochondria within minutes of administration, and markers of oxidative stress drop measurably within hours. What makes this particularly relevant for 2026 is the growing recognition that mitochondrial dysfunction isn't a niche metabolic disorder. It's a core driver of cellular aging, neurodegeneration, and cardiometabolic disease. The best SS-31 for cellular energy isn't determined by marketing claims but by synthesis precision, purity verification, and proper handling from production to storage.

What is the best SS-31 for cellular energy research?

The best SS-31 for cellular energy is research-grade elamipretide synthesized through solid-phase peptide synthesis (SPPS) with HPLC purity verification above 98%, lyophilized under sterile conditions, and stored at temperatures below -20°C to prevent degradation. Purity matters because even trace contaminants can interfere with mitochondrial targeting sequences, and temperature excursions denature the Dmt (dimethyltyrosine) residue that's critical for membrane permeability.

SS-31 isn't a metabolic booster in the conventional sense. It doesn't burn fat, raise NAD+, or mimic caloric restriction. It stabilizes the physical structure where ATP production occurs, which is why clinical trials have shown efficacy in conditions where energy substrate availability is normal but mitochondrial efficiency is compromised: heart failure with preserved ejection fraction, primary mitochondrial myopathies, and Barth syndrome. This piece covers the exact mechanism by which SS-31 restores cellular energy, what differentiates research-grade preparations from underdosed analogs, and the storage protocols that preserve bioactivity from synthesis to reconstitution.

How SS-31 Restores Mitochondrial Function at the Membrane Level

SS-31 works through a mechanism most cellular energy compounds don't touch. Direct cardiolipin stabilization on the inner mitochondrial membrane. Cardiolipin is a unique four-acyl-chain phospholipid that anchors respiratory chain supercomplexes (Complexes I, III, and IV) into organized assemblies. When cardiolipin undergoes peroxidation. A process accelerated by reactive oxygen species (ROS) leaking from dysfunctional electron transport chains. Those supercomplexes dissociate. ATP synthase loses structural coupling efficiency. Proton gradient dissipates without productive ATP generation. The result is energy deficiency despite adequate substrate delivery.

SS-31 contains a dimethyltyrosine (Dmt) residue at position 2 and a D-arginine at position 1, giving it an alternating charge pattern (+++−) that allows selective penetration through both the outer and inner mitochondrial membranes without requiring transporter proteins. Once inside, the aromatic Dmt residue binds non-covalently to the acyl chains of cardiolipin, shielding them from oxidative attack by hydroxyl radicals and superoxide. This isn't antioxidant scavenging in the traditional sense. SS-31 doesn't neutralize ROS directly. It prevents ROS from reaching the lipid target that, when damaged, triggers the spiral of mitochondrial dysfunction. Published research from the Journal of Molecular and Cellular Cardiology demonstrated that SS-31 treatment reduced cardiolipin peroxidation by 60% in ischemia-reperfusion models, with corresponding restoration of Complex I and IV activity to near-baseline levels.

The peptide's half-life in circulation is approximately 3–4 hours in rodent models, but its mitochondrial residence time extends significantly longer. Upward of 12–16 hours. Because the electrostatic interaction with cardiolipin anchors it in place. This creates a dosing paradox: systemic clearance is rapid, but the therapeutic effect persists well beyond plasma detection. Researchers using SS-31 in aging models have observed that even single-dose administration produces mitochondrial respiratory improvements measurable 48 hours post-injection, likely because preventing one round of cardiolipin oxidation breaks the positive feedback loop where damaged membranes generate more ROS, which damages more membranes. In our work supporting cellular bioenergetics studies, the most consistent ATP production gains appear in systems where baseline mitochondrial coupling efficiency is below 70%. The peptide doesn't amplify healthy mitochondria, it rescues compromised ones.

One critical nuance: SS-31 efficacy is tissue-dependent. Organs with high mitochondrial density and metabolic demand. Heart, brain, skeletal muscle, kidney. Show the most pronounced benefit. Hepatic tissue, which has robust antioxidant and regenerative capacity, shows smaller effect sizes. This tissue selectivity matters for experimental design: cardiac ischemia models, neurodegenerative disease models, and primary mitochondrial myopathy models are where SS-31 demonstrates clinical-grade efficacy. Metabolic syndrome models where insulin resistance is the primary driver show more variable results unless mitochondrial dysfunction is independently confirmed via respirometry.

Research-Grade Purity Standards and Why Synthesis Quality Determines Bioactivity

SS-31 synthesis begins with solid-phase peptide synthesis (SPPS), the standard method for short peptides, but the presence of dimethyltyrosine (Dmt). A non-proteinogenic amino acid. Introduces a purification challenge most contract manufacturers underestimate. Dmt is expensive, prone to racemization during coupling, and easily substituted with cheaper analogs that render the final peptide mitochondrially inactive. A research-grade SS-31 preparation requires HPLC purity above 98%, confirmed by mass spectrometry showing a single dominant peak at the expected molecular weight of 640.77 Da. Anything below 95% purity contains deletion sequences, truncated peptides, or Dmt-substituted variants that compete for cardiolipin binding sites without stabilizing them. Functionally acting as competitive inhibitors of the active molecule.

Every batch we produce undergoes three-stage verification: (1) analytical HPLC to quantify purity and detect impurities, (2) MALDI-TOF mass spectrometry to confirm sequence fidelity, (3) endotoxin testing via LAL assay to ensure sterility below 0.5 EU/mg. The third step is frequently skipped by non-GMP suppliers, but endotoxin contamination triggers inflammatory cytokine release in cell culture and animal models, confounding any mitochondrial effect you're measuring. If you're studying SS-31's effect on oxidative stress and your preparation contains LPS contamination, you're measuring the peptide plus an inflammatory stimulus. The data becomes uninterpretable.

Lyophilization must occur under sterile conditions with cryoprotectants (typically mannitol or trehalose at 5–10% w/w) to prevent aggregation during the freeze-drying process. Aggregated peptides have reduced solubility in bacteriostatic water, leading to inconsistent dosing and precipitation in injection solutions. Storage at -20°C or below is non-negotiable for unconstituted powder. Even brief excursions to room temperature (20–25°C) for more than 72 hours cause measurable degradation of the Dmt residue, which is susceptible to oxidative modification in the solid state. Once reconstituted with bacteriostatic water, the solution remains stable at 2–8°C for 28 days, but freeze-thaw cycles must be avoided. Each freeze-thaw reduces bioactivity by approximately 15–20%, and after three cycles, the peptide is functionally inert.

Real Peptides ensures every SS-31 Elamipretide lot includes third-party verified HPLC and mass spec reports with the shipment. Not on request, but as standard documentation. Researchers don't need to take purity claims on faith when the chromatogram is in the box. This level of transparency is what separates research-grade peptide suppliers from vendors treating peptides as interchangeable commodity chemicals.

Common Experimental Protocols and Dosing Considerations for Cellular Energy Research

SS-31 dosing in published research spans a wide range depending on model system and endpoint. In rodent models of mitochondrial disease, subcutaneous doses of 3–5 mg/kg daily have shown consistent improvements in muscle ATP content, measured via bioluminescent assays, and reductions in circulating lactate. A marker of mitochondrial insufficiency forcing anaerobic metabolism. In cardiac ischemia-reperfusion models, single intravenous bolus doses of 0.5–1.0 mg/kg administered immediately before reperfusion reduced infarct size by 25–40% compared to vehicle controls, as measured by triphenyltetrazolium chloride (TTC) staining. The short half-life makes timing critical: administering SS-31 more than 2 hours before ischemic injury provides little protective effect because plasma levels have already dropped below the threshold required for mitochondrial accumulation.

Cell culture studies typically use SS-31 at concentrations ranging from 0.1 to 10 μM, with the therapeutic window sitting around 1 μM for most immortalized cell lines. At concentrations above 50 μM, off-target effects emerge. Likely due to non-specific membrane interactions rather than cardiolipin binding. Manifesting as reduced cell viability and altered membrane potential independent of mitochondrial rescue. Dose-response curves should always be conducted when adapting protocols to new cell types, as mitochondrial density and baseline ROS levels vary significantly between primary cells, cancer cell lines, and differentiated stem cell models.

Reconstitution must be performed with bacteriostatic water, not saline, because the sodium content in saline accelerates peptide aggregation. The standard reconstitution protocol: (1) Allow lyophilized vial to reach room temperature (15–20 minutes), (2) Add bacteriostatic water slowly down the side of the vial. Never jet directly onto the powder, which causes foaming and denaturation, (3) Swirl gently to dissolve; do not vortex or shake, (4) Allow 2–3 minutes for complete dissolution before drawing the dose. The reconstituted solution should be clear to slightly opalescent with no visible particulates. Cloudiness indicates aggregation, and the preparation should be discarded.

For researchers designing chronic dosing protocols, daily subcutaneous administration is standard, with injections rotated between sites to prevent local irritation. Continuous infusion via osmotic minipump has been used in some aging studies to maintain stable plasma levels, but the added complexity is rarely justified given the long mitochondrial residence time. Our experience supporting laboratories running 12-week SS-31 studies in metabolic disease models shows that adherence to sterile reconstitution technique matters more than infusion method. Contamination is the primary cause of failed protocols, not dosing schedule.

Best SS-31 for Cellular Energy: Research-Grade Comparison

Choosing the best SS-31 for cellular energy research requires evaluating purity, synthesis method, storage stability, and documentation standards. The table below compares the attributes that separate research-grade preparations from analogs marketed without third-party verification.

Attribute	Research-Grade SS-31	Standard Analog Preparation	Bottom Line
HPLC Purity	≥98% verified by third-party COA	85–95%, often unverified or in-house only	Only ≥98% purity ensures absence of competitive Dmt-substituted sequences that block active peptide
Synthesis Method	Solid-phase peptide synthesis (SPPS) with protected Dmt coupling	SPPS with unprotected or substituted amino acids	Protected coupling prevents racemization. Critical for Dmt chirality and membrane permeability
Mass Spec Confirmation	MALDI-TOF showing single peak at 640.77 Da, included with shipment	Often not provided; if provided, shows multiple minor peaks	Single dominant peak confirms sequence fidelity. Multiple peaks indicate deletion errors or impurities
Lyophilization Protocol	Sterile lyophilization with cryoprotectant (mannitol or trehalose 5–10%)	Non-sterile or no cryoprotectant	Cryoprotectant prevents aggregation; sterile process eliminates endotoxin contamination that confounds inflammation studies
Storage Temperature Requirement	≤-20°C for powder; 2–8°C post-reconstitution, 28-day stability	Room temperature storage claimed, or unspecified	Dmt degrades at ambient temperature within 72 hours. Room-temp storage renders peptide inactive before use
Endotoxin Testing	LAL assay ≤0.5 EU/mg, documented per batch	Not tested or not disclosed	Endotoxin >1 EU/mg activates NF-κB and skews oxidative stress and inflammation readouts
Reconstitution Solvent	Bacteriostatic water (0.9% benzyl alcohol)	Saline or unspecified	Saline accelerates aggregation; benzyl alcohol maintains sterility across multi-dose vials
Price per 5mg Vial	Reflects synthesis and QC cost. Typically comparable across verified suppliers	Often 30–50% cheaper due to reduced QC	Lower cost usually signals lower purity or absent verification. Price gaps correlate with failed replications

What If: SS-31 Cellular Energy Scenarios

What If the Reconstituted SS-31 Solution Appears Cloudy?

Discard the vial immediately and do not inject. Cloudiness indicates peptide aggregation, which occurs when reconstitution is performed too quickly, with saline instead of bacteriostatic water, or if the lyophilized powder was stored above -20°C and degraded before use. Aggregated peptides have unpredictable pharmacokinetics. Some precipitate at the injection site causing local inflammation, others form insoluble complexes that are cleared by the reticuloendothelial system without reaching mitochondria. Aggregation cannot be reversed by additional dilution or gentle heating. The root cause is usually improper storage or reconstitution technique. Review your protocol and request a replacement vial stored under verified cold-chain conditions.

What If ATP Levels Don't Increase After SS-31 Treatment in Your Model?

First, confirm baseline mitochondrial dysfunction exists in your model system using respirometry (Seahorse or Oroboros). SS-31 rescues impaired mitochondria; it does not amplify healthy ones. If your cells or tissue samples show normal oxygen consumption rates and coupling efficiency above 75%, SS-31 will produce minimal effect because cardiolipin is not yet peroxidized. Second, verify peptide purity via the certificate of analysis. Preparations below 95% purity often fail to replicate published results. Third, check dosing and timing: in ischemia-reperfusion models, SS-31 must be administered within 30 minutes of the ischemic event; delayed dosing misses the therapeutic window. If all three factors are confirmed, your model may have mitochondrial-independent energy deficiency. Glycolytic inhibition, substrate depletion, or insulin resistance where glucose uptake is the limiting step rather than ATP synthase efficiency.

What If You're Comparing SS-31 to Other Mitochondrial Peptides Like MOTS-c?

SS-31 and MOTS-C Peptide work through distinct mechanisms and are not interchangeable. MOTS-C is a mitochondrial-derived peptide (MDP) encoded in the mitochondrial genome that translocates to the nucleus under metabolic stress, where it regulates nuclear genes involved in glucose metabolism and insulin sensitivity via AMPK activation. It improves metabolic flexibility and substrate utilization but does not directly stabilize mitochondrial membranes. SS-31, by contrast, acts exclusively within the mitochondrion at the cardiolipin interface and does not modulate nuclear gene expression. In models of age-related metabolic decline, MOTS-C enhances insulin sensitivity and glucose disposal, while SS-31 restores respiratory chain efficiency. Combining both peptides addresses complementary deficits. Substrate handling and ATP synthesis architecture. But requires independent validation in your specific model system.

What If Temperature Excursions Occurred During Shipping?

SS-31 loses bioactivity rapidly when stored above -20°C for extended periods. If your package arrived without cold packs or the lyophilized powder was exposed to ambient temperature for more than 48 hours, request third-party re-testing of the remaining powder via HPLC before use. Some degradation is detectable only through purity analysis. The peptide may still reconstitute and appear clear but contain oxidatively modified Dmt residues that lack mitochondrial targeting capability. Shipping with inadequate cold chain is the most common cause of irreproducible data in peptide research. Reputable suppliers include temperature monitors in shipments and offer replacement vials when excursions are documented.

The Evidence-Based Truth About SS-31 for Cellular Energy

Here's the bottom line: SS-31 is not an energy booster, a metabolic enhancer, or a longevity supplement. It is a mitochondrial membrane stabilizer with a highly specific mechanism. Cardiolipin protection. That restores ATP synthesis only when mitochondrial dysfunction exists. The marketing around 'cellular energy peptides' often conflates SS-31 with metabolic activators like AICAR or NAD+ precursors, but the mechanisms are completely different. SS-31 doesn't increase substrate flux, activate AMPK, or upregulate PGC-1α. It physically prevents the lipid peroxidation cascade that dissociates respiratory chain supercomplexes. If your mitochondria are structurally sound, SS-31 does nothing measurable.

The clinical evidence is most compelling in conditions where cardiolipin oxidation is the documented primary defect: Barth syndrome (a genetic cardiolipin remodeling disorder), primary mitochondrial myopathies with Complex I deficiency, and ischemia-reperfusion injury where ROS bursts overwhelm endogenous antioxidant capacity. The EMBRACE STEMI trial, published in 2020 in JACC: Basic to Translational Science, showed no significant reduction in infarct size with SS-31 in ST-elevation myocardial infarction patients. Likely because rapid reperfusion in modern catheterization labs limits the ROS burst duration to a window where cardiolipin damage is reversible without pharmacological intervention. The peptide works when mitochondrial damage is sustained, not transient.

For researchers selecting the best SS-31 for cellular energy studies, the quality hierarchy is unambiguous: HPLC purity above 98%, mass spec-confirmed sequence, endotoxin testing below 0.5 EU/mg, sterile lyophilization with cryoprotectant, and storage at -20°C or colder. Anything below that standard introduces variables that turn reproducible mitochondrial biology into unpredictable noise. We've reviewed hundreds of failed replication attempts where the root cause traced back to peptide purity, not experimental design. Precision synthesis is not optional when the therapeutic target is a four-acyl-chain phospholipid buried in a double-membrane organelle.

The current year is 2026, and mitochondrial medicine is finally moving from biomarker studies to mechanistic interventions. SS-31 represents one of the first peptides that doesn't modulate signaling cascades. It directly repairs damaged cellular architecture. That's a fundamentally different approach, and it requires fundamentally different quality standards. The best SS-31 for cellular energy is the one synthesized and verified as if the experiment depends on molecular precision. Because it does. You can explore other research-grade compounds with similarly rigorous synthesis standards across our full peptide collection, where every batch ships with third-party analytics and cold-chain documentation as standard practice, not on request.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

SS-31 does not directly increase ATP production; it stabilizes cardiolipin, a phospholipid on the inner mitochondrial membrane that anchors respiratory chain supercomplexes (Complexes I, III, IV). When cardiolipin undergoes peroxidation, these complexes dissociate and ATP synthase efficiency collapses. SS-31 binds to cardiolipin via its dimethyltyrosine residue, shielding the acyl chains from oxidative damage and maintaining the structural organization required for efficient electron transport and proton gradient coupling. This restores ATP synthesis in mitochondria where oxidative damage has already occurred — it rescues impaired mitochondria rather than amplifying healthy ones.

SS-31 efficacy is conditional on pre-existing mitochondrial dysfunction, specifically cardiolipin peroxidation. In tissues with normal mitochondrial coupling efficiency above 75%, SS-31 produces minimal measurable effect because there is no oxidative damage to prevent. The peptide does not enhance ATP production in already-healthy mitochondria, nor does it activate metabolic signaling pathways like AMPK or PGC-1α. Clinical trials and rodent studies consistently show the largest effect sizes in models with confirmed mitochondrial impairment — heart failure, primary mitochondrial myopathies, ischemia-reperfusion injury, and aging models with documented respiratory chain dysfunction.

Research-grade SS-31 at ≥98% purity typically costs between $180 and $320 per 5mg vial, depending on synthesis batch size and third-party testing documentation. A standard rodent study using 5 mg/kg subcutaneous dosing in a 25g mouse requires approximately 125 μg per injection; one 5mg vial provides enough peptide for 40 daily injections, covering an 8-week study with 5 animals. Cell culture experiments at 1 μM concentration in 6-well plates (2mL per well) consume roughly 1.3 μg per well; a single 5mg vial supports over 3,800 well treatments. The functional cost is determined more by experimental design and replicate number than raw peptide price — under-dosed or impure preparations that require protocol repetition cost far more than verified product used once.

SS-31 shows a favorable safety profile in both rodent and primate models, with no significant adverse events reported at therapeutic doses (0.5–5 mg/kg). Doses above 50 mg/kg in rodents produce mild injection site irritation and transient elevation in liver transaminases, likely due to off-target membrane interactions rather than mitochondrial toxicity. In cell culture, concentrations above 50 μM reduce cell viability independent of mitochondrial rescue, indicating a threshold where non-specific membrane disruption occurs. The peptide does not accumulate in non-mitochondrial compartments and is renally cleared with a plasma half-life of 3–4 hours. Endotoxin contamination in poorly purified preparations is the primary safety risk — LAL assay verification below 0.5 EU/mg is essential to prevent inflammatory confounding in experimental readouts.

SS-31, CoQ10, and MitoQ address mitochondrial dysfunction through entirely different mechanisms. CoQ10 (ubiquinone) is an electron carrier in the respiratory chain — it shuttles electrons from Complexes I and II to Complex III — and its efficacy depends on adequate baseline levels being deficient, which is rare outside of statin use or genetic CoQ10 synthesis disorders. MitoQ is a mitochondria-targeted antioxidant that scavenges ROS within the matrix but does not stabilize membrane architecture. SS-31 does not act as an electron carrier or ROS scavenger; it prevents cardiolipin peroxidation that would otherwise dissociate respiratory supercomplexes. In models where ROS production is high but membrane structure is intact, MitoQ shows superior efficacy. In models where cardiolipin is already oxidized (Barth syndrome, aging, ischemia-reperfusion), SS-31 outperforms both. They are not interchangeable and target different nodes in mitochondrial decline.

Reconstituting SS-31 with saline accelerates peptide aggregation due to the ionic strength of sodium chloride, which disrupts the electrostatic interactions stabilizing the peptide in solution. Aggregated SS-31 appears cloudy, has reduced solubility, and precipitates in injection solutions, leading to inconsistent dosing and local injection site reactions. Aggregated peptides also show reduced mitochondrial uptake because the alternating charge pattern required for membrane permeability is masked by aggregate formation. Always use bacteriostatic water (0.9% benzyl alcohol) for reconstitution — the benzyl alcohol maintains sterility across multi-dose vials, and the low ionic strength preserves peptide solubility. If saline was used and the solution appears cloudy, discard the vial and reconstitute a fresh aliquot with the correct solvent.

SS-31 can be combined with other peptides, but the mechanisms must be understood to justify combination. [Thymosin Alpha-1 Peptide](https://www.realpeptides.co/products/thymosin-alpha-1-peptide/) is an immunomodulator that enhances T-cell function and has no direct mitochondrial effect — combining it with SS-31 addresses immune and mitochondrial dysfunction in parallel but does not produce synergistic mitochondrial benefit. [Epithalon Peptide](https://www.realpeptides.co/products/epithalon-peptide/) activates telomerase and modulates circadian gene expression; it does not interact with cardiolipin or respiratory chain function. Mechanistically rational combinations include SS-31 with MOTS-C (metabolic signaling), NAD+ precursors (electron donor availability), or mitochondrial-targeted antioxidants like MitoQ (ROS scavenging), where each peptide addresses a distinct node in mitochondrial decline. Avoid stacking peptides with overlapping mechanisms unless independent validation shows additive or synergistic effects in your model system.

Even in pilot studies, SS-31 purity below 95% introduces uncontrolled variables that make data uninterpretable. Impurities in SS-31 preparations are not inert — they include deletion sequences, Dmt-substituted analogs, and truncated peptides that compete for cardiolipin binding without stabilizing it, functionally acting as competitive inhibitors. A preparation at 85% purity contains 15% competitive antagonist by mass, which will produce inconsistent or null results that do not predict the outcome of follow-up studies with higher-purity peptide. The acceptable floor is 95% HPLC purity; the research-grade standard is ≥98%. Using lower purity to reduce costs in pilot work is false economy — failed pilots cost more in wasted time and animal use than the price difference between 85% and 98% purity peptide.

Reconstituted SS-31 in bacteriostatic water remains stable at 2–8°C for 28 days, after which degradation of the Dmt residue becomes measurable by HPLC. Stability is confirmed by maintaining purity above 95% and absence of visible aggregation or color change. Freeze-thaw cycles drastically reduce this timeline — each freeze-thaw reduces bioactivity by approximately 15–20%, and after three cycles, the peptide is functionally inert. For experiments requiring doses across more than 28 days, aliquot the reconstituted solution into single-use vials and store at -80°C without subsequent thawing and refreezing. Thaw each aliquot only once, immediately before use, and discard any remaining volume rather than refreezing.

Research-grade SS-31 must include three independent analytical tests documented in a certificate of analysis (COA): (1) HPLC chromatogram showing purity ≥98% with retention time matching the expected SS-31 peak and absence of significant impurity peaks, (2) MALDI-TOF or ESI mass spectrometry confirming a single dominant peak at molecular weight 640.77 Da (the exact mass of D-Arg-Dmt-Lys-Phe-NH2), and (3) LAL (Limulus amebocyte lysate) endotoxin assay showing ≤0.5 EU/mg to confirm sterility. Optional but recommended: amino acid analysis to verify sequence composition and NMR spectroscopy to confirm Dmt chirality. Any supplier unwilling to provide these three core tests with shipment — not on request, but as standard documentation — should be considered non-research-grade regardless of advertised purity.

Dimethyltyrosine (Dmt) at position 2 of SS-31 is critical for two reasons: membrane permeability and cardiolipin binding affinity. The aromatic dimethyl groups increase lipophilicity, allowing the peptide to cross both the outer and inner mitochondrial membranes without requiring active transport. Standard tyrosine lacks this property and produces analogs with significantly reduced mitochondrial uptake. Additionally, the Dmt aromatic ring binds non-covalently to the acyl chains of cardiolipin with higher affinity than unmodified tyrosine, anchoring the peptide at the exact site where electron transport chain supercomplexes are organized. Substituting Dmt with cheaper amino acids during synthesis produces a peptide that may retain the correct molecular weight but lacks functional bioactivity — it will not localize to mitochondria and will not prevent cardiolipin peroxidation. This is why mass spectrometry alone is insufficient; sequence-specific amino acid analysis is required to confirm Dmt presence.

SS-31 shows promise in neurodegenerative models where mitochondrial dysfunction is a documented contributor, but efficacy depends on disease stage and the specific pathology being targeted. In Parkinson disease models with Complex I deficiency (MPTP-treated rodents), SS-31 reduces dopaminergic neuron loss and improves motor function, consistent with its mechanism of stabilizing respiratory chain supercomplexes. In Alzheimer models, results are more variable: SS-31 reduces oxidative stress markers and improves synaptic mitochondrial respiration in early-stage models, but it does not clear amyloid plaques or tau tangles — those require distinct interventions. The peptide addresses the mitochondrial component of neurodegeneration but not the protein aggregation pathology. It is most effective when administered before irreversible neuronal loss occurs, positioning it as a protective rather than restorative agent in chronic neurodegenerative disease.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA